ABBVIE INC. vs. Mineralys Therapeutics, Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ABBV | MLYS | |
|---|---|---|
| Market Cap | $462.49 billion | $2.50 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | $-349,576,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | MLYS | |
|---|---|---|
| P/E Ratio | 73.51 | — |
| Price / Book | -78.55 | 4.54 |
| Price / Sales | 7.18 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | MLYS | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | -63.45% |
MLYS leads on 1 of 1 profitability factors.
Dividend
| ABBV | MLYS | |
|---|---|---|
| Dividend Yield | 2.66% | — |
| Payout Ratio | 195.48 | — |
ABBV and MLYS split the dividend factors evenly.
Risk & Sentiment
| ABBV | MLYS | |
|---|---|---|
| Short Interest | 0.85% | 0.06% |
MLYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, MLYS overview, MLYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.